• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 3rd December 2020

The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’

Bernarda Zamora presented at the virtual event entitled ‘Value of Diagnostic Information in Heart Failure’, which was organised by Roche Diagnostics. The panel, composed of six experts representing a range of stakeholders across Europe, shared their insights and perspectives on…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Bernarda Zamora presented at the virtual event entitled ‘Value of Diagnostic Information in Heart Failure’, which was organised by Roche Diagnostics. The panel, composed of six experts representing a range of stakeholders across Europe, shared their insights and perspectives on the Value of Diagnostic Information (VODI), and explored policies and changes that need to be made to capture the outcomes of diagnostic information in heart failure treatment and management.

On 16 November 2020, Bernarda Zamora presented at the virtual event Value of Diagnostic Information in Heart Failure, which was organised by Roche Diagnostics. This event continued the efforts of the Value of Diagnostic Information (VODI) platform towards the promotion and implementation of the VODI concept developed through stakeholders’ discussions with MedTech Europe. The panel, composed of six experts representing a range of stakeholders across Europe, shared their insights on the Value Of Diagnostic Information and explored policies and changes that need to be made to better measure the value of diagnostic information in heart failure (HF) treatment and management.

HF is a common and complex syndrome where the heart becomes too weak or stiff to pump enough blood through the body. The health and economic burden of HF is large and well-documented. One in five people can expect to be diagnosed with HF at some point in their lives, facing survival rates worse than major cancers, and being the most common cause of hospital admissions in people over the age of 65. Early diagnosis has an important impact both on improving survival rates and on reducing the direct and indirect costs of HF care to health systems and society. However, common symptoms between HF and other diseases make it challenging for healthcare professionals to confirm or rule out HF. Diagnostic information is needed to diagnose HF timely and accurately, and this is facilitated by in vitro diagnostics (IVDs), such as the blood test N-terminal pro-brain natriuretic peptide (NT-proBNP).

The VODI framework outlines how to define and measure the value of outcomes created by IVDs, and how to incorporate this information into decision-making processes. The VODI concept was introduced by the panel moderator, Mr Ed Harding, Network Director of the Heart Failure Policy Network, followed by presentations from Ms Sophie Marie Meiser, Manager of Market Access and Economic Policies at MedTech Europe, and Bernarda Zamora, Senior Economist at the Office of Health Economics. They stipulated the challenge that exists to appropriately measure and reward the value generated by IVDs, as derived from information used by healthcare professionals in decision-making. In contrast to therapeutics, this value is not observed as a direct clinical benefit and it must be captured through the ‘value chain’ triggered by healthcare professionals with the diagnosis, that spills over to patients, healthcare providers, healthcare systems and society overall. To overcome this challenge, the VODI framework is designed to be holistic: it accounts for the full range of potential benefits of diagnostic testing, beyond the traditional clinical and health economic domains. This is essential to recognise, measure, fully leverage and reward the benefits of diagnostics for patients, health systems, and society.

Source: Wurcel et al. 2019.

Healthcare professionals were represented at the panel by Professor Yigal M Pinto of the Heart Centre at the Academic Medical Centre in The Netherlands, and by Ms Carys Barton, Heart Failure Nurse Consultant at Imperial College Healthcare NHS Trust and Chair of the British Society for Heart Failure Nurse Forum. Both stressed the importance of more and earlier diagnosis. For example, 40% of HF patients that are hospitalised in the UK display symptoms that should have triggered earlier investigations. With better use of NT-proBNP testing in primary care, hospitalisation can be avoided through timely diagnosis of HF and initiation of guideline-recommended therapies, and selection and optimisation of complex treatment choices. To capture the clinical benefit, it is important to measure clinical endpoints along the patient pathway. While new treatments have demonstrated considerable survival benefits in clinical trials, it is much more difficult to determine treatment benefit in real-world settings. The effect of diagnostic tests such as NT-proBNP should be measured in clinical endpoints including hospital admission rate as well as survival.

Patients’ views were brought forward by Mr Nick Hartshorne-Evans, Founder and Chief Executive of the Pumping Marvellous Foundation in the UK. Patients’ testimonies expressed how delayed diagnosis or misdiagnosis of HF has had a detrimental impact on their psychological wellbeing, quality of life and employment of people first experiencing symptoms of HF. People living with HF have reported increased levels of stress, anxiety, and depression due to delays in their diagnostic process. Moreover, there is a lack of awareness of IVDs tests. The measurement of biomarkers relevant to HF, such as NT-proBNP and others, ideally as part of routine blood tests at a one-stop HF clinic, would contribute to increasing the awareness of signs and symptoms of HF among the public and healthcare professionals.

A view from the industry and the healthcare system was presented by Professor Damien Gruson, Head of Lab, Cliniques universitaires Saint-Luc, Belgium; and Member of the European Commission’s Expert Panel on Effective Ways of Investing in Health. In particular, he stressed the importance of point-of-care devices and new laboratory testing services in primary care that can support the timely diagnosis of HF. The use of point-of-care devices, notably, has been valuable during the COVID-19 pandemic by enabling real-time monitoring of HF patients. The information generated by these devices, coupled with clinical data, can further improve diagnosis and better characterise a person’s HF. This would support the delivery of personalised HF care and treatment, which may lead to improved cardiovascular outcomes and potentially generate substantial cost savings.

The panel session ended with a discussion of questions and comments raised by attendees, including several suggestions for incentivising the use of diagnostics in HF. The panel concluded that:

  1. Increasing awareness among healthcare professionals of the VODI along the HF care pathway is the first step to trigger the value chain;
  2. Implementation should be facilitated by funding support and reimbursement of high-value diagnostics tests, including tests in primary care; and
  3. The information collected from real-world data should be shared and analysed, which would require investments in information-technology systems that currently sit in silos.

Related Research:

Wurcel V, Cicchetti A, Garrison L, Kip M, M, A, Koffijberg H, Kolbe A, Leeflang M, M, G, Merlin T, Mestre-Ferrandiz J, Oortwijn W, Oosterwijk C, Tunis S, Zamora B. 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics. 22, pp. 8-15. doi: 10.1159/000501832

  • Precision Medicine
  • Economics of Innovation
  • Innovation

Related Insights

Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!